New drug trial offers hope for slowing type 1 diabetes progression
A groundbreaking clinical trial has shown that the drug teplizumab can delay the onset of type 1 diabetes by an average of two years in high-risk individuals. The treatment, which targets the immune system, offers hope for those identified as being at risk of developing the condition. Researchers describe it as a “pivotal moment” in type 1 diabetes care, though caution that more work is needed to understand long-term effects and accessibility.
